Absolutely. Very interesting question. A CHIP risk score actually has been developed using patients in the UK Biobank, but this is just a general population. A lot of different things went into creating this risk score. One of the main things being the specific type of CHIP mutation, how many CHIP mutations there are as well. Additionally, patient’s age. So those are some of the biggest ones that go into that risk score...
Absolutely. Very interesting question. A CHIP risk score actually has been developed using patients in the UK Biobank, but this is just a general population. A lot of different things went into creating this risk score. One of the main things being the specific type of CHIP mutation, how many CHIP mutations there are as well. Additionally, patient’s age. So those are some of the biggest ones that go into that risk score. But actually, with my mentor, Dr Jennifer Kwan, we published a paper last year in the Journal of the American College of Cardiology showing that this risk score doesn’t necessarily translate to a cancer population specifically. So we know that while it has been shown to risk stratify well in the general population, in cancer patients, a new risk score definitely is needed. And so a lot of work needs to be done in this field, especially focusing on these cancer patients and understanding more about the specific things that need to go into this risk score. For instance, the different types of cancer medications that they receive or other types of research definitely need to be done to figure out what types of things need to go into the risk score.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
